ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TENX Tenax Therapeutics Inc

4.21
0.34 (8.79%)
Last Updated: 12:51:26
Delayed by 15 minutes

Period:

Draw Mode:

Volume 151,674
Bid Price 4.20
Ask Price 4.23
News (1)
Day High 4.25

Low
3.48

52 Week Range

High
61.152

Day Low 3.86
Company Name Stock Ticker Symbol Market Type
Tenax Therapeutics Inc TENX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.34 8.79% 4.21 12:51:26
Open Price Low Price High Price Close Price Prev Close
3.94 3.86 4.25 3.87
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
782 151,674 $ 4.07 $ 616,730 - 3.48 - 61.152
Last Trade Time Type Quantity Stock Price Currency
12:53:33 15 $ 4.25 USD

Tenax Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.2M 298.28k - 0 -11.05M -37.04 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Tenax Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TENX Message Board. Create One! See More Posts on TENX Message Board See More Message Board Posts

Historical TENX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.964.253.483.8045,5290.256.31%
1 Month4.215.16953.484.48153,5750.000.00%
3 Months15.7221.45993.488.90368,862-11.51-73.22%
6 Months23.88861.1523.4843.413,812,906-19.68-82.38%
1 Year40.70461.1523.4840.962,270,434-36.49-89.66%
3 Years3,264.003,952.003.48338.291,673,068-3,259.79-99.87%
5 Years3,504.005,888.003.481,085.491,379,471-3,499.79-99.88%

Tenax Therapeutics Description

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com.

Your Recent History

Delayed Upgrade Clock